A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Study Purpose

This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Relapsed or refractory MM with measurable disease per IMWG guidelines as defined by at least 1 of the following: 1. Serum M-protein ≥0.5 g/dL (≥5 g/L) by serum protein electrophoresis (SPEP) or, for immunoglobulin (Ig) A or D myeloma, by quantitative serum IgA or IgD levels ≥ 0.5 g/dL. 2. Urinary M-protein excretion ≥200 mg/24 hours. 3. Serum free light chain (FLC) ≥100 mg/L, provided that the FLC ratio is abnormal (normal FLC ratio: 0.26 to 1.65) 2. Received at least 1 and no more than 4 prior anti-MM lines of therapy. Induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1 line of therapy. 3. Patients must have prior therapy which must include an anti-CD3 mAb, and ≥2 consecutive cycles of the following agents given alone or in combinations: lenalidomide, proteasome inhibitor. 4. Patients must have prior therapy with anti-CD38 mAb in one of the following ways: 1. Received anti-CD38 mAb as their immediate last treatment prior to study entry (50% of patients) 2. Received prior anti-CD38 mAb other than in immediate last treatment prior to study entry (50% of patients) 5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2. 6. Resolution of any clinically significant non-hematological toxicities (if any) from previous treatments to Grade ≤1 by Cycle 1 Day 1 (C1D1). Patients with Grade 2 non-hematological toxicities may be included following approval from the Medical Monitor. 7. Adequate hepatic function within 28 days prior to C1D1: 1. Total bilirubin <2 × upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of <3 × ULN) 2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5 × ULN. 8. Adequate renal function within 28 days prior to C1D1 (estimated creatinine clearance [CrCl] of ≥15 mL/min (not requiring dialysis), calculated using the formula of Cockcroft and Gault or measured by 24-hour urine collection). 9. Adequate hematopoietic function within 7 days prior to C1D1 defined as absolute neutrophil count ≥1.5 x 109/L , hemoglobin ≥8.5 g/dL, and platelet count ≥100 x 109/L (patients for whom <50% of bone marrow nucleated cells are plasma cells) or ≥75 x 109/L (patients for whom ≥50% of bone marrow nucleated cells are plasma cells). 1. Patients receiving hematopoietic growth factor support, including erythropoietin, darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and platelet stimulators (e.g., eltrombopag, romiplostim, or interleukin-11) must have a 2-week interval between growth factor support and the Screening assessments, but they may receive growth factor support during the study. 2. Patients must have:
  • - At least a 2-week interval from the last red blood cell (RBC) transfusion prior to the Screening hemoglobin assessment, and.
  • - At least a 1-week interval from the last platelet transfusion prior to the Screening platelet assessment.
However, patients may receive RBC and/or platelet transfusions as clinically indicated per institutional guidelines during the study. 10. Female patients of childbearing potential must have a negative serum pregnancy test within 10 to 14 days and a second test within 24 hours prior to the first dose of study treatment. Female patients of childbearing potential and fertile male patients who are sexually active must use highly effective methods of contraception throughout the study and for 3 months following the last dose of study treatment. 11. Age ≥18 years at the time of signing informed consent. 12. Written informed consent signed in accordance with federal, local, and institutional guidelines. 13. Patients must be able and willing to take enteric-coated aspirin according to clinical practice, or if history of prior thrombotic disease, must be fully anticoagulated with warfarin (international normalized ratio [INR] 2-3) or be treated with full-dose, low molecular weight heparin, as if to treat deep venous thrombosis (DVT)/pulmonary embolism (PE) at the Investigator's discretion.

Exclusion Criteria:

1. Smoldering MM. 2. Plasma cell leukemia. 3. Documented active systemic amyloid light chain amyloidosis. 4. Active central nervous system MM. 5. Prior treatment with: 1. A selective inhibitor of nuclear export (SINE) compound, including selinexor. 2. Pomalidomide and/or elotuzumab. 6. Any concurrent medical condition or disease that is likely to interfere with study procedures. 7. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to C1D1. Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable. 8. Known intolerance, hypersensitivity, or contraindication to any of the study treatments. 9. Radiation, chemotherapy, or immunotherapy or any other anticancer therapy including investigational therapies and high dose dexamethasone (i.e., 40 mg daily for 4 days per week) ≤2 weeks prior to C1D1. Patients on long-term glucocorticoids during Screening do not require a washout period but must be able to tolerate the specified dexamethasone dose in this study. 10. Prior autologous stem cell transplantation <60 days or allogeneic stem cell transplantation <4 months prior to C1D1. 11. Major surgery within 4 weeks prior to C1D1. 12. Active graft versus host disease after allogeneic stem cell transplantation. 13. Pregnant or breastfeeding females. 14. In the opinion of the Investigator, patients who are below their ideal body weight and would be unduly impacted by changes in their weight. 15. Clinically significant cardiac disease, including: 1. Myocardial infarction within 6 months before C1D1, or unstable or uncontrolled disease/condition related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, New York Heart Association Class III-IV). 2. Uncontrolled cardiac arrhythmia (CTCAE v. 5.0 Grade 2 or higher) or clinically significant electrocardiogram (ECG) abnormalities. 3. Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) >470 msec. 16. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment. 17. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent. 18. Contraindication to any of the required concomitant drugs or supportive treatments. 19. Patients unwilling or unable to comply with the protocol.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05028348
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

European Myeloma Network
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other, Industry
Overall Status Recruiting
Countries France, Germany, Greece, Italy, Netherlands, Spain, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Multiple Myeloma
Arms & Interventions

Arms

Experimental: Selinexor, pomalidomide and dexamethasone (SPd)

Selinexor will be given as an oral dose 40 mg (2 20 mg tablets) or 60 mg (3 20 mg tablets) once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle. Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle. Patients ≤75 years: o Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Dose may be divided over 2 days at the Investigator's discretion. Patients > 75 years: Dexamethasone will be given as an oral 20 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Dose may be divided over 2 days at the Investigator's discretion.

Active Comparator: Elotuzumab, Pomalidomide and Dexamethasone (EloPd)

Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle. Pomalidomide will be given as an oral 4 mg dose once a day (QD) on Days 1 to 21 of each 28-day cycle. Patients ≤75 years: Dexamethasone 28 mg PO + 8 mg IV on days of elotuzumab dosing Dexamethasone 40 mg PO on non-elotuzumab days (e.g., days 8, 15, and 22 of cycle 3 and beyond). Dose may be divided over 2 days at the Investigator's discretion. Patients >75 years: Dexamethasone 8 mg PO + 8 mg IV on days of elotuzumab dosing Dexamethasone 20 mg PO on non-elotuzumab dosing weeks (e.g., days 8, 15, and 22 of cycle 3 and beyond). Dose may be divided over 2 days at the Investigator's discretion.

Interventions

Drug: - Selinexor

Selinexor will be given as an oral dose 40 mg (2 20 mg tablets) or 60 mg (3 20 mg tablets) QW on Days 1, 8, 15, and 22 of each 28-day cycle.

Drug: - Elotuzumab

Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle.

Drug: - Pomalidomide

Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.

Drug: - Dexamethasone Oral

Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Preferred dosing of dexamethasone is 40 mg QW for patients who are ≤75 years of age (20 mg QW for >75-year-old patients at the Investigator's discretion) before QW dosing of selinexor, however, it may be divided over 2 days at the Investigator's discretion.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

The University of Arizona Cancer Center, Tucson, Arizona

Status

Not yet recruiting

Address

The University of Arizona Cancer Center

Tucson, Arizona, 85724

Site Contact

Muhammad Husnain

chiara.pautasso@emnitaly.org

+31 107033123

University of California, San Francisco, Fresno, California

Status

Not yet recruiting

Address

University of California, San Francisco

Fresno, California, 93701

Site Contact

Haifaa Abdulhaq

chiara.pautasso@emnitaly.org

+31 107033123

Kaiser Permanente Southern California, Irvine, California

Status

Not yet recruiting

Address

Kaiser Permanente Southern California

Irvine, California, 92618

Site Contact

Ashraf Aziz

chiara.pautasso@emnitaly.org

+31 107033123

Los Angeles, California

Status

Recruiting

Address

Los Angeles Hematology Oncology Medical Group

Los Angeles, California, 90017

Site Contact

Lasika Seneviratne

chiara.pautasso@emnitaly.org

+31 107033123

Berenson Oncology, West Hollywood, California

Status

Recruiting

Address

Berenson Oncology

West Hollywood, California, 90069

Site Contact

James Berenson

chiara.pautasso@emnitaly.org

+31 107033123

Whittier, California

Status

Recruiting

Address

The Oncology Institute of Hope and Innovation

Whittier, California, 90602

Site Contact

Merrill Shum

chiara.pautasso@emnitaly.org

+31 107033123

UCHealth Cancer Center - Harmony Campus, Fort Collins, Colorado

Status

Not yet recruiting

Address

UCHealth Cancer Center - Harmony Campus

Fort Collins, Colorado, 80528

Site Contact

Steven Schuster

chiara.pautasso@emnitaly.org

+31 107033123

Florida Cancer Specialists South, Fort Myers, Florida

Status

Not yet recruiting

Address

Florida Cancer Specialists South

Fort Myers, Florida, 33901

Site Contact

Faithlore Gardner

chiara.pautasso@emnitaly.org

+31 107033123

Florida Cancer Specialists North, Saint Petersburg, Florida

Status

Not yet recruiting

Address

Florida Cancer Specialists North

Saint Petersburg, Florida, 33705

Site Contact

Gustavo Fonseca

chiara.pautasso@emnitaly.org

+31 107033123

Florida Cancer Specialists Panhandle, Tallahassee, Florida

Status

Not yet recruiting

Address

Florida Cancer Specialists Panhandle

Tallahassee, Florida, 32308

Site Contact

Viralkumar Bhanderi

chiara.pautasso@emnitaly.org

+31 107033123

Florida Cancer Specialists East, West Palm Beach, Florida

Status

Not yet recruiting

Address

Florida Cancer Specialists East

West Palm Beach, Florida, 33401

Site Contact

Shachar Peles

chiara.pautasso@emnitaly.org

+31 107033123

Hawaii Cancer Care, Honolulu, Hawaii

Status

Recruiting

Address

Hawaii Cancer Care

Honolulu, Hawaii, 96813

June E. Nylen Cancer Center, Sioux City, Iowa

Status

Not yet recruiting

Address

June E. Nylen Cancer Center

Sioux City, Iowa, 51101

Site Contact

Donald Wender

chiara.pautasso@emnitaly.org

+31 107033123

Hematology Oncology Clinic, Baton Rouge, Louisiana

Status

Recruiting

Address

Hematology Oncology Clinic

Baton Rouge, Louisiana, 70809

Site Contact

Michael Castine

chiara.pautasso@emnitaly.org

+31 107033123

American Oncology Partners of Maryland, Bethesda, Maryland

Status

Recruiting

Address

American Oncology Partners of Maryland

Bethesda, Maryland, 20817

Site Contact

Ralph Boccia

chiara.pautasso@emnitaly.org

+31 107033123

Ascension St. John Hospital, Grosse Pointe Woods, Michigan

Status

Not yet recruiting

Address

Ascension St. John Hospital

Grosse Pointe Woods, Michigan, 48236

Site Contact

Daniel Lebovic

chiara.pautasso@emnitaly.org

+31 107033123

Nebraska Hematology - Oncology, P.C., Lincoln, Nebraska

Status

Recruiting

Address

Nebraska Hematology - Oncology, P.C.

Lincoln, Nebraska, 68506

Site Contact

Irfan Vaziri

chiara.pautasso@emnitaly.org

+31 107033123

Cancer Care Specialists, Reno, Nevada

Status

Recruiting

Address

Cancer Care Specialists

Reno, Nevada, 89511

Site Contact

Subramanyeswara Arekapudi

chiara.pautasso@emnitaly.org

+31 107033123

MD Anderson Cancer Center at Cooper, Camden, New Jersey

Status

Not yet recruiting

Address

MD Anderson Cancer Center at Cooper

Camden, New Jersey, 08103-1461

Site Contact

Tulin Budak-Alpdogan

chiara.pautasso@emnitaly.org

+31 107033123

East Carolina University, Greenville, North Carolina

Status

Not yet recruiting

Address

East Carolina University

Greenville, North Carolina, 27834

Site Contact

Darla Liles

chiara.pautasso@emnitaly.org

+31 107033123

Novant Health Cancer Institute, Winston-Salem, North Carolina

Status

Not yet recruiting

Address

Novant Health Cancer Institute

Winston-Salem, North Carolina, 27103

Site Contact

Franklin Chen

chiara.pautasso@emnitaly.org

+31 107033123

West Reading, Pennsylvania

Status

Recruiting

Address

Reading Hospital - McGlinn Cancer Institute

West Reading, Pennsylvania, 19611

Site Contact

Terrence Cescon

chiara.pautasso@emnitaly.org

+31 107033123

Charleston, South Carolina

Status

Not yet recruiting

Address

Medical University of South Carolina. Hollings Cancer Center

Charleston, South Carolina, 29425

Site Contact

Hamza Hashni

chiara.pautasso@emnitaly.org

+31 107033123

Gibbs Cancer Center, Spartanburg, South Carolina

Status

Not yet recruiting

Address

Gibbs Cancer Center

Spartanburg, South Carolina, 29303

Site Contact

Tondre Buck

chiara.pautasso@emnitaly.org

+31 107033123

Renovatio Clinical Research, The Woodlands, Texas

Status

Recruiting

Address

Renovatio Clinical Research

The Woodlands, Texas, 77380

Site Contact

Jonathan Lu

chiara.pautasso@emnitaly.org

+31 107033123

International Sites

CHRU Hôpital Claude Huriez, Lille, France

Status

Not yet recruiting

Address

CHRU Hôpital Claude Huriez

Lille, ,

CHRU Hôtel Dieu, Nantes, France

Status

Recruiting

Address

CHRU Hôtel Dieu

Nantes, ,

CHU Hôpital Saint Antoine, Paris, France

Status

Not yet recruiting

Address

CHU Hôpital Saint Antoine

Paris, ,

La Pitié, Paris, France

Status

Not yet recruiting

Address

La Pitié

Paris, ,

Paris Necker, Paris, France

Status

Not yet recruiting

Address

Paris Necker

Paris, ,

Poitiers, France

Status

Not yet recruiting

Address

CHU Poitiers - Pôle régional de Cancérologie

Poitiers, ,

Pôle IUCT Oncopole CHU, Toulouse, France

Status

Not yet recruiting

Address

Pôle IUCT Oncopole CHU

Toulouse, ,

Universitätsklinikum Hamburg - Eppendorf, Hamburg, Germany

Status

Not yet recruiting

Address

Universitätsklinikum Hamburg - Eppendorf

Hamburg, ,

University Hospital of Heidelberg, Heidelberg, Germany

Status

Not yet recruiting

Address

University Hospital of Heidelberg

Heidelberg, ,

University Hospital of Cologne, Köln, Germany

Status

Not yet recruiting

Address

University Hospital of Cologne

Köln, ,

University Hospital of Münster, Münster, Germany

Status

Not yet recruiting

Address

University Hospital of Münster

Münster, ,

Site Contact

Khandanpour

chiara.pautasso@emnitaly.org

+31 107033123

University Hospital of Würzburg, Würzburg, Germany

Status

Not yet recruiting

Address

University Hospital of Würzburg

Würzburg, ,

Athens, Greece

Status

Recruiting

Address

Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens

Athens, ,

Site Contact

Evangelos Terpos

chiara.pautasso@emnitaly.org

+31 107033123

General Hospital of Athens"Evangelismos", Athens, Greece

Status

Recruiting

Address

General Hospital of Athens"Evangelismos"

Athens, ,

St Savvas Cancer Hospital, Athens, Greece

Status

Not yet recruiting

Address

St Savvas Cancer Hospital

Athens, ,

University General Hospital of Patras, Patras, Greece

Status

Not yet recruiting

Address

University General Hospital of Patras

Patras, ,

Theagenion Cancer Hospital, Thessaloníki, Greece

Status

Not yet recruiting

Address

Theagenion Cancer Hospital

Thessaloníki, ,

Ancona, Italy

Status

Not yet recruiting

Address

Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi Di Ancona

Ancona, ,

A.O. Papa Giovanni XXIII, Bergamo, Italy

Status

Not yet recruiting

Address

A.O. Papa Giovanni XXIII

Bergamo, ,

Bologna, Bologna, Italy

Status

Not yet recruiting

Address

Bologna

Bologna, ,

Brescia, Italy

Status

Not yet recruiting

Address

ASST Spedali Civili di Brescia - Ematologia

Brescia, ,

Site Contact

Angelo Belotti, MD

chiara.pautasso@emnitaly.org

+31 107033123

Brescia, Brescia, Italy

Status

Not yet recruiting

Address

Brescia

Brescia, ,

Ospedale Oncologico 'A. Businco', Cagliari, Italy

Status

Not yet recruiting

Address

Ospedale Oncologico 'A. Businco'

Cagliari, ,

Az.Osp. Di Careggi_Dh ematologia, Firenze, Italy

Status

Not yet recruiting

Address

Az.Osp. Di Careggi_Dh ematologia

Firenze, , 50134

Site Contact

Alberto Bosi, MD

alberto.bosi@unifi.it

055794111

Genova, Italy

Status

Not yet recruiting

Address

A.O.U. Policlinico S. Martino - Ematologia

Genova, ,

Hospital IRST, Meldola, Italy

Status

Not yet recruiting

Address

Hospital IRST

Meldola, ,

A.O.U. Policlinico 'G. Martino', Messina, Italy

Status

Not yet recruiting

Address

A.O.U. Policlinico 'G. Martino'

Messina, ,

A.O.U. Maggiore della Carità di Novara, Novara, Italy

Status

Not yet recruiting

Address

A.O.U. Maggiore della Carità di Novara

Novara, , 28100

Site Contact

Andrea Novali

amministrazione@emnresearch.it

+393924398409

Ospedale S. Eugenio, Roma, Italy

Status

Not yet recruiting

Address

Ospedale S. Eugenio

Roma, ,

Site Contact

De Fabritiis

chiara.pautasso@emnitaly.org

+31 107033123

A.O. S. Maria, Terni, Italy

Status

Not yet recruiting

Address

A.O. S. Maria

Terni, ,

Torino, Italy

Status

Not yet recruiting

Address

A.O.U. Città della Salute e della Scienza di Torino - SC Ematologia U

Torino, , 10126

Site Contact

Alessandra Larocca, MD

chiara.pautasso@emnitaly.org

+31 107033123

Udine, Italy

Status

Not yet recruiting

Address

Azienda Ospedaliera Universitaria di Udine

Udine, ,

Site Contact

Francesca Patriarca, MD-PhD

patriarca.francesca@aoud.sanita.fvg.it

+31 107033123

Amphia ziekenhuis, Breda, Netherlands

Status

Not yet recruiting

Address

Amphia ziekenhuis

Breda, ,

Site Contact

van der Klift

chiara.pautasso@emnitaly.org

+31 107033123

Erasmus MC, Rotterdam, Netherlands

Status

Not yet recruiting

Address

Erasmus MC

Rotterdam, ,

Barcelona, Spain

Status

Recruiting

Address

Hospital Clinic I Provincial de Barcelona

Barcelona, ,

Barcelona, Spain

Status

Recruiting

Address

Institut Catala D Oncolocia Hospitalet - Hospital Duran i Reynals

Barcelona, ,

Hospital Universitario 12 de Octubre, Madrid, Spain

Status

Recruiting

Address

Hospital Universitario 12 de Octubre

Madrid, ,

Site Contact

Martínez-López

chiara.pautasso@emnitaly.org

+31 107033123

Murcia, Spain

Status

Recruiting

Address

H. General Universitario Morales Meseguer

Murcia, ,

Site Contact

De Arriba de la Fuerte

chiara.pautasso@emnitaly.org

+31 107033123

Clínica Universidad de Navarra (CUN), Pamplona, Spain

Status

Recruiting

Address

Clínica Universidad de Navarra (CUN)

Pamplona, ,

Hospital Universitario de Salamanca, Salamanca, Spain

Status

Not yet recruiting

Address

Hospital Universitario de Salamanca

Salamanca, ,

H. Universitario Marqués de Valdecilla, Santander, Spain

Status

Recruiting

Address

H. Universitario Marqués de Valdecilla

Santander, ,

Santiago De Compostela, Spain

Status

Recruiting

Address

Complejo Hospitalario Universitario de Santiago (CHUS)

Santiago De Compostela, ,

Site Contact

Gonzalez Pérez

chiara.pautasso@emnitaly.org

+31 107033123

H.U. La Fe, Valencia, Spain

Status

Recruiting

Address

H.U. La Fe

Valencia, ,

Site Contact

de la Rubia

chiara.pautasso@emnitaly.org

+31 107033123